Lupin Limited (LUPIN) - Financial and Strategic SWOT Analysis Review

Date: September 27, 2016
Pages: 59
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L4AC4EF7847EN
Leaflet:

Download PDF Leaflet

Lupin Limited (LUPIN) - Financial and Strategic SWOT Analysis Review
Lupin Limited (LUPIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Lupin Limited (Lupin) is transnational pharmaceutical company. It is one of the leading generic pharmaceutical companies across the world. The company focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, anti-infectives, NSAIDs, anti-TB and cephalosporins. The company undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. It has operations in various countries worldwide including India, the US, the UK, Germany, Japan, South Africa, Philippines, and Australia. Lupin is headquartered in Mumbai, Maharashtra, India.

Lupin Limited Key Recent Developments

Aug 09, 2016: Lupin: Record Sales Profits - Quarter I FY2017
Aug 09, 2016: Lupin announces first quarter ended June 30, 2016 financila results
Jul 08, 2016: US FDA Audit at Lupin’s Dabhasa Facility, 29th June – 06th July 2016
Jul 07, 2016: Lupin receives EIR from US FDA for Goa, July 2015 Inspection
Jun 07, 2016: Lupin Appoints Yugesh Goutam as President – Global HR

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Lupin Limited - Key Facts
Lupin Limited - Key Employees
Lupin Limited - Key Employee Biographies
Lupin Limited - Major Products and Services
Lupin Limited - Pharmaceutical Pipeline Products Data
Lupin Limited, Pipeline Products by Therapy Area
Lupin Limited, Pipeline Products by Development Phase
Lupin Limited - History
Lupin Limited - Company Statement
Lupin Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Lupin Limited - Business Description
Lupin Limited - Corporate Strategy
Lupin Limited - SWOT Analysis
SWOT Analysis - Overview
Lupin Limited - Strengths
Strength - Strong Market Presence
Strength - Portfolio of Generic Products
Strength - Revenue Driven by Increased Sales in India
Lupin Limited - Weaknesses
Weakness - Manufacturing Defects Leads to Recall
Lupin Limited - Opportunities
Opportunity - Inorganic Growth Drivers: Acquisitions
Opportunity - New Product Approvals and Launches
Opportunity - Business Initiatives
Lupin Limited - Threats
Threat - Competitive Pressures
Threat - Uncertain R&D Activities
Threat - Stringent Government Regulations
Lupin Limited - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Lupin Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Lupin Limited, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 09, 2016: Lupin: Record Sales Profits - Quarter I FY2017
Aug 09, 2016: Lupin announces first quarter ended June 30, 2016 financila results
Jul 07, 2016: Lupin receives EIR from US FDA for Goa, July 2015 Inspection
Jun 07, 2016: Lupin Appoints Yugesh Goutam as President – Global HR
May 26, 2016: Lupin announces closure of US FDA Audits for its Mandideep and Aurangabad Facilities
May 19, 2016: Record Sales & Profits – A New High Quarter IV & Annual Results - FY2016 Q4 FY2016 Net Sales up 34.0%, EBITDA up 72.7%, Net profit up 47.5% Proposed Dividend 375%
Apr 05, 2016: Lupin Appoints Dr. Kurt Nielsen as President of Lupin - Somerset
Feb 05, 2016: Lupin Announces the results for the quarter ended December 31, 2015
Nov 24, 2015: Lupin Receives FDA Approvals for Generic Loestrin Fe 1/20 and Loestrin 1.5/30 Tablets
Nov 05, 2015: Lupin Appoints Thierry Volle as President - Europe, Middle-East & Africa (EMEA)

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Lupin Limited, Key Facts
Lupin Limited, Key Employees
Lupin Limited, Key Employee Biographies
Lupin Limited, Major Products and Services
Lupin Limited, Number of Pipeline Products by Therapy Area
Lupin Limited, Number of Pipeline Products by Development Stage
Lupin Limited, Pipeline Products By Therapy Area and Development Phase
Lupin Limited, History
Lupin Limited, Other Locations
Lupin Limited, Subsidiaries
Lupin Limited, Joint Venture
Lupin Limited, Key Competitors
Lupin Limited, Ratios based on current share price
Lupin Limited, Annual Ratios
Lupin Limited, Interim Ratios
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Lupin Limited, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Lupin Limited, Pipeline Products by Therapy Area
Lupin Limited, Pipeline Products by Development Phase
Lupin Limited, Performance Chart (2012 - 2016)
Lupin Limited, Ratio Charts
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Lupin Limited, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Sun Pharmaceutical Industries Limited
Lincon Pharmaceuticals Ltd
Intas Pharmaceuticals Ltd.
Dr. Reddy's Laboratories Limited
Divi's Laboratories Limited
Cipla Ltd.
Abbott India Limited
Aarti Drugs Ltd.
Skip to top


Ask Your Question

Lupin Limited (LUPIN) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: